Rituximab utilization for approved and off‐label nononcology indications and patients’ experiences with the Patient Alert Card

This study used retrospective chart review and survey data to evaluate: (1) off‐label use of rituximab (MabThera(®)/Rituxan(®)) in autoimmune conditions and (2) patients’ receipt and knowledge of the Patient Alert Card (PAC), a risk minimization measure for progressive multifocal leukoencephalopathy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarsour, Khaled, Beckley‐Kartey, Senam, Melega, Simone, Odueyungbo, Adefowope, Kirchner, Petra, Khalife, Natasha, Bangs, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941895/
https://www.ncbi.nlm.nih.gov/pubmed/31911839
http://dx.doi.org/10.1002/prp2.555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941895/
https://www.ncbi.nlm.nih.gov/pubmed/31911839
http://dx.doi.org/10.1002/prp2.555

Ejemplares similares